REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/29/2026
Back to search
Official data from USPTO
ÆTERNA ZENTARIS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
06/29/2026
Trademark type
Combined
Nice classes
5
Filing date
09/01/2020
Registration date
06/29/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/29/2021
Last transaction
06/29/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
99
Owner location
Frankfurt am Main, DE
Examiner
JACKSON, STEVEN W
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized wavy line in the shape of a sideways infinity symbol on a slight tilt to the right with the tail ends in azure and the middle swoop in dark lime green followed by the word "ÆTERNA" in thin dark lime green letters above the word "ZENTARIS" in thick azure letters.
Holders and representatives
Holders
Æterna Zentaris GmbH
Representatives
Victoria Friedman DENNEMEYER & ASSOCIATES LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations used for the treatment of cancer; pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer; pharmaceutical preparations used for the treatment of urological diseases; pharmaceutical preparations used for the treatment of hormonal disorders; synthetic peptides-containing pharmaceutical preparations used for hormonal and tumors treatments; pharmaceutical preparations used for the treatment of endocrine diseases; pharmaceutical preparations used for the treatment of carcinoid tumors; pharmaceutical preparations used for the treatment of haematological diseases; pharmaceutical preparations used for the treatment of age-related diseases; pharmaceutical preparations used for the treatment of ophthalmological disorders; pharmaceutical preparations used for the treatment of reproductive system disorders; pharmaceutical preparations used for the treatment of endometriosis; pharmaceutical preparations used for the treatment of uterine myoma; pharmaceutical preparations used for the treatment of non-malignant tumors; pharmaceutical preparations used for the treatment of benign prostatic hyperplasia; pharmaceutical preparations used for the treatment of tropical diseases; pharmaceutical preparations used for the treatment of infectious disease; pharmaceutical preparations used for the treatment of leishmaniasis; pharmaceutical preparations used for the treatment of obesity; pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes; pharmaceutical preparations containing cytotoxic productsconjugated or notfor the treatment of cancer or infectious diseases; pharmaceutical preparations used as a tubulin inhibitor for the treatment of cancer; pharmaceutical preparations based on LHRH antagonists platform for the treatment of cancerhormonal tumorshormonal disorders; pharmaceutical preparations based on bombesin antagonist platform for the treatment of cancer; pharmaceutical preparations based on inhibitors of the Akt pathway for the treatment of cancer or infectious diseases; pharmaceutical preparations based on angiogenesis inhibitors platform for the treatment of cancer; pharmaceutical preparations used to induce apoptosis; pharmaceutical preparations used to stimulate growth hormone secretagogue; vaccines for the treatment of tumors; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases; diagnostic agentspreparations and substances for medical purposes; pharmaceutical productscomprising growth hormone secretagoguesghrelin receptor agonistsghrelin receptor antagonistsghrelin mimeticsgrowth hormone analoguesgrowth hormone fusion proteinsgrowth hormone releasing hormone analoguesauto immune modulating proteinstherapeutic antibodiessmall molecule kinase inhibitorsphospholipids for the treatment of neurological disorders; pharmaceutical preparations for the treatment of nasopharyngeal disorders; antibiotics; antibacterial and fungicidal preparations; pharmaceutical preparations for the treatment of mental health; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of rheumatoid diseases; pharmaceutical preparations for contraceptives and women's health; analgesic pharmaceutical productscomprising small molecule kinase inhibitorsphospholipidstherapeutic antibodiesnatural products; sedativa and pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for palliative treatments; pharmaceutical preparations for the treatment of addictions; pharmaceutical formulations for the treatment of paediatric indications
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/29/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/13/2021
PUBO
PUBLISHED FOR OPPOSITION
04/13/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/24/2021
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
03/10/2021
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
03/05/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/26/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/26/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/26/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/12/2021
GNRT
NON-FINAL ACTION E-MAILED
01/12/2021
CNRT
NON-FINAL ACTION WRITTEN
01/12/2021
DOCK
ASSIGNED TO EXAMINER
01/06/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/07/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/06/2020
NWAP
NEW APPLICATION ENTERED
09/04/2020
Continuous trademark protection
Get notified about every new filing that threatens ÆTERNA ZENTARIS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.